These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37003209)

  • 1. Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma.
    Liu Y; Lu T; Yuan M; Chen R; Lu J; Wang H; Wu Z; Wang Y
    Lung Cancer; 2023 May; 179():107169. PubMed ID: 37003209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
    Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
    Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma.
    Xie M; Chen D; Li Y; Liu X; Kuang D; Li X
    Diagn Pathol; 2022 Feb; 17(1):30. PubMed ID: 35172862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
    Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
    J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens.
    Zhao L; Huang S; Liu J; Zhao J; Li Q; Wang HQ
    Medicine (Baltimore); 2017 Sep; 96(39):e8153. PubMed ID: 28953659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
    Zuo Y; Zhong J; Bai H; Xu B; Wang Z; Li W; Chen Y; Jin S; Wang S; Wang X; Wan R; Xu J; Fei K; Han J; Yang Z; Bao H; Shao Y; Ying J; Song Q; Duan J; Wang J
    EBioMedicine; 2022 Aug; 82():104165. PubMed ID: 35901658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation,
    Yang M; Yu P; He Z; Deng J
    Front Immunol; 2023; 14():1266304. PubMed ID: 38332908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
    PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
    Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
    Yang H; Chen H; Luo S; Li L; Zhou S; Shen R; Lin H; Xie X
    Oncotarget; 2017 Apr; 8(14):23517-23528. PubMed ID: 28423587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
    Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.